Cargando…

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

INTRODUCTION: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment setting. AXL, a member of the TYRO3, AXL, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Ryota, Fujii, Hiroyuki, Yamada, Tadaaki, Matsui, Yohei, Yaoi, Takeshi, Honda, Mizuki, Tanaka, Noriyuki, Miyagawa-Hayashino, Aya, Yoshimura, Akihiro, Morimoto, Kenji, Iwasaku, Masahiro, Tokuda, Shinsaku, Kim, Young Hak, Konishi, Eiichi, Itoh, Kyoko, Takayama, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329144/ https://www.ncbi.nlm.nih.gov/pubmed/37426308 http://dx.doi.org/10.1016/j.jtocrr.2023.100525

Ejemplares similares

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)
por: Kawachi, Hayato, et al.
Publicado: (2023)

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
por: Takei, Shota, et al.
Publicado: (2023)

Prognostic significance of spatial immune profiles in human solid cancers
por: Tsujikawa, Takahiro, et al.
Publicado: (2020)

Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer
por: Seto, Yurie, et al.
Publicado: (2022)

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer
por: Nakamura, Ryota, et al.
Publicado: (2023)

TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection
por: Miyagawa-Hayashino, Aya, et al.
Publicado: (2021)

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
por: Ishida, Masaki, et al.
Publicado: (2021)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study
por: Morimoto, Kenji, et al.
Publicado: (2022)

Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report
por: Seto, Yurie, et al.
Publicado: (2023)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
por: Morimoto, Kenji, et al.
Publicado: (2022)

Acute Monocytic Leukemia Masquerading Behçet's Disease-Like Illness at Onset in an Elderly Female
por: Koba, Shigeru, et al.
Publicado: (2016)

Spatial Profiles of Intratumoral PD-1(+) Helper T Cells Predict Prognosis in Head and Neck Squamous Cell Carcinoma
por: Yoshimura, Kanako, et al.
Publicado: (2021)

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer
por: Tanaka, Satomi, et al.
Publicado: (2022)

Primary CNS CD45-Depleted T-Cell Lymphoma: The First Pathologically Confirmed Case
por: Morisako, Tamaki, et al.
Publicado: (2020)

Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study
por: Seto, Yurie, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
por: Onoi, Keisuke, et al.
Publicado: (2020)

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
por: Okura, Naoko, et al.
Publicado: (2020)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)

Loss of Aspm causes increased apoptosis of developing neural cells during mouse cerebral corticogenesis
por: Tonosaki, Madoka, et al.
Publicado: (2023)

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
por: Yoshimura, Akihiro, et al.
Publicado: (2022)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Low Doses of Bisphenol A Disrupt Neuronal Differentiation of Human Neuronal Stem/Progenitor Cells
por: Kiso-Farnè, Kaori, et al.
Publicado: (2022)

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study
por: Uda, Sayaka, et al.
Publicado: (2022)

Advanced G‐CSF‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy
por: Matsui, Yohei, et al.
Publicado: (2020)

Multiple primary lung adenocarcinomas pre‐operatively diagnosed by discordant epidermal growth factor receptor mutations
por: Katayama, Yuki, et al.
Publicado: (2019)

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
por: Morimoto, Kenji, et al.
Publicado: (2021)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

Diagnosis of unexposed tumours using endobronchial ultrasonography with a guide sheath and a thin transbronchial needle
por: Kuno, Haruka, et al.
Publicado: (2021)

An autopsy case of COVID‐19 with a sudden death: Clinico‐pathological comparison
por: Shishido‐Hara, Yukiko, et al.
Publicado: (2022)

The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels
por: Fritz, Helena K., et al.
Publicado: (2015)

Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant
por: Tomida, Akimasa, et al.
Publicado: (2022)

SPS proposal: study on Event Structures of 200 GeV/Nucleon $^{32}$S interactions with nuclei by the magnetic emulsion spectrometer at the CERN SPS
por: Itoh, H, et al.
Publicado: (1989)

Immune Evasion Mechanism and AXL
por: Son, Hye-Youn, et al.
Publicado: (2021)

Patent Spring Washer Axles
Publicado: (1878)

Cannot write session to /tmp/vufind_sessions/sess_h5kkk860cg0qbknpoh7affo07p